Why Bristol-Myers returned angiostatin

EntreMed Inc. has decided to push into human trials with a compound that partner Bristol-Myers Squibb Co. believes is not ready for clinical development, reflecting the differing sense of urgency between a biotech company with nothing in the clinic and a pharma company with product sales and a broad oncology pipeline.

While the proof of who is right will be seen in clinical trials, the main point of disagreement is whether ENMD's highly publicized anti-angiogenic protein material is potent, scalable and reproducible enough to take forward...